Navigation Links
Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
Date:7/10/2012

SAN FRANCISCO, July 10, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the private placement of $125 million of 12.0% Senior Secured Notes Due in 2017 in an offering exempt from the registration requirements of the Securities Act of 1933.  Nektar intends to use the net proceeds from the offering of the Senior Secured Notes towards the repayment of its Convertible Subordinated Notes due September 28, 2012.  The sale of the Senior Secured Notes is expected to close on July 11, 2012, subject to customary closing conditions.

"Today's $125 million secured notes placement, combined with the royalty sale we completed in the first quarter, significantly strengthens our cash position with no dilution to our shareholders," said Howard W. Robin, President and Chief Executive Officer of Nektar. "After repayment of all of our outstanding convertible debt, we expect to have approximately $300 million in cash and equivalents at the end of 2012, which should provide Nektar with multiple years of working capital."

The notes are callable by Nektar beginning in July 2015, subject to certain prepayment premiums and conditions. The Senior Secured Notes are not subject to financial performance targets. For further details on the terms and conditions of the Senior Secured Notes, please refer to the Form 8-K which is expected to be filed with the Securities and Exchange Commission following the anticipated close of the transaction on July 11, 2012.

The Senior Secured Notes and related note guarantees to be offered will not be and have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or a solicitation of an offer to buy such notes or note guarantees and is issued in
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
2. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
3. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
4. United Therapeutics Announces Additional $100 Million Share Repurchase Program
5. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
6. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
9. Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
10. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
11. Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , Jan. 26 The following is a ... PharmAthene, regarding the Commission on the Prevention of Weapons of ... Card by the Commission on the Prevention of Weapons of ... America still remains vulnerable to bioterrorism.  Our Nation,s ability to ...
... , , TUALATIN, Ore. ... Bulletin Board: WYNX), a platform company dedicated to the ... announced that it has reached an agreement with British-based ... second generation Gas Quality Inferential Measurement Device (GasPT2). , ...
... Jan. 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... that it may now enroll patients at US clinical sites ... lead product, nimotuzumab. One of the two trials is in ... treatment and being treated palliatively and the other in patients ...
Cached Biology Technology:Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 2Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 2YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 3YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 5
(Date:7/9/2014)... New Rochelle, NY, July 9, 2014Biofuels derived from the ... alternative to fossil fuels. To achieve this goal, optimization ... as in open pond systems, is needed. Sapphire Energy ... contamination of open pond algae cultivation systems, described in ... Ann Liebert, Inc., publishers. The article is available on ...
(Date:7/9/2014)... a University of Guelph scientist that involved fitting ... exposure to a neonicotinoid pesticide hampers bees, ability ... Nigel Raine, a professor in Guelph,s School of ... London was published July 9 in the British ... The study shows how long-term pesticide exposure affects ...
(Date:7/9/2014)... A new study shows that some shark species may be ... that may come with rising temperatures. , The Arctic today ... but it wasn,t always like that. Roughly 53 to 38 ... epoch, the Arctic was more similar to a huge temperate ... life, including ancestors of tapirs, hippo-like creatures, crocodiles and giant ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Bee foraging chronically impaired by pesticide exposure: Study 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... researchers have identified the job of one of the ... puzzled scientists because it is present in nearly every ... and yet, in laboratory experiments, its function has remained ... enigmatic enzyme known as DinB DNA polymerase is specialized ...
... have identified a handful of microRNAs (miRNAs) that appear ... platelets ?blood cells critical to the body's ability to ... of these same miRNAs, when acting abnormally, may contribute ... that a specific set of miRNA genes are turned ...
... and slow developing gills appear to be keys to ... fish whose adults thrive in icy waters because of ... are important, researchers at the University of Illinois atUrbana-Champaign ... species of notothenioids that inhabit the Ross Sea at ...
Cached Biology News:Common enzyme is a key player in DNA repair 2Common enzyme is a key player in DNA repair 3MiRNA fingerprint identified in platelet formation 2Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: